Visiongain has published a new report entitled Pharma Wholesale and Distribution Market Report 2025-2035 (Including Impact of U.S. Trade Tariffs): Forecasts by Type ((Wholesalers (Producer Wholesaler, Merchant Wholesaler, Agents and Brokers), Distributor (Single Party Distributor, and Multi Party Distributor)), by Distribution Type ((Ethical/Branded Pharma Products Distributors, Generic Pharma Products Distributors, Propaganda Cum Distribution (PCD) Franchise, OTC/Institutional Supply Pharma Distributors, Others)), by Product Type (Branded Pharmaceuticals, Generic Pharmaceuticals, Over-the-counter (OTC) Pharmaceuticals, Vaccines, Medical Devices, Others), by End-users (Hospitals & Clinics, Retail Pharmacies, Online/E-Pharmacies, Others) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies.

The global Pharma Wholesale and Distribution market is estimated at US$ 1,033 billion in 2025 and is projected to grow at a CAGR of 7.8% during the forecast period 2025-2035.

Impact of US Trade Tariffs on the Global Pharma Wholesale and Distribution Market   

U.S. trade tariffs are reshaping the operating economics of pharma wholesale and distribution. Tariffs applied to APIs, intermediates, excipients, packaging materials and finished-dose imports from China, India and Europe immediately increase landed costs and compress already-thin distributor margins. This forces wholesalers to revisit pricing across branded, generic and OTC portfolios and, in many cases, renegotiate terms with manufacturers and institutional buyers.

Operationally, tariffs introduce uncertainty into procurement cycles by extending lead times and adding customs complexity. Distributors must hold higher inventory buffers and allocate more working capital to protect service levels. For multi-party distributors and institutional supply models, tariff swings complicate budgeting and contract stability.

Tariffs may also shift sourcing patterns toward tariff-neutral regions, altering warehousing and fulfilment routes. Overall, U.S. tariffs increase cost volatility and planning risk, pushing wholesalers to build more diversified, resilient sourcing and distribution strategies.

Emerging-Market Distributors Scale Up Through Aggressive M&A and Integration

Recent high-impact acquisitions in the pharmaceutical sector are signalling a shift toward more sophisticated, capability-intensive wholesale and distribution networks. In October 2024, Mankind Pharma completed its landmark acquisition of Bharat Serums and Vaccines (BSV), expanding its presence in specialty and hospital-focused therapies across critical care, fertility, and women’s health. These therapy classes rely on compliant, temperature-controlled, and institution-ready distribution pathways. As Mankind integrates BSV’s complex portfolio, demand intensifies for national distributors with robust cold-chain infrastructure, sterile-product handling, and reliable penetration into hospitals and speciality clinics—particularly across emerging markets where logistical fragmentation persists.

Similarly, in January 2025, GSK entered into an agreement to acquire IDRx, a precision oncology developer advancing mutation-targeted cancer therapies. Such highly specialised portfolios require wholesale partners capable of managing stringent integrity requirements, enhanced demand visibility, and closer coordination with oncologists, speciality pharmacies, and tertiary-care centres.

Together, these two transactions reinforce a structural market trend: as manufacturers scale deeper into biologics, specialty therapies and precision medicines, wholesale and distribution networks must evolve toward higher service sophistication, integrated national platforms, and advanced compliance capabilities to support increasingly complex product flows.

How will this Report Benefit you?

Visiongain’s 303-page report provides 112 tables and 158 charts/graphs. Our new study is suitable for anyone requiring commercial, in-depth analyses for the Pharma Wholesale and Distribution market, along with detailed segment analysis in the market. Our new study will help you evaluate the overall global and regional market for Pharma Wholesale and Distribution. Get financial analysis of the overall market and different segments including type, process, upstream, downstream, and company size and capture higher market share. We believe that there are strong opportunities in this fast-growing Pharma Wholesale and Distribution market. See how to use the existing and upcoming opportunities in this market to gain revenue benefits in the near future. Moreover, the report will help you to improve your strategic decision-making, allowing you to frame growth strategies, reinforce the analysis of other market players, and maximise the productivity of the company.

What are the Current Market Drivers?

Rising Specialty and GLP-1 Volumes Are Reshaping Wholesale Infrastructure

The sharp increase in specialty medicines, biologics and GLP-1 therapies is redefining how wholesale networks need to operate. These products require dependable cold-chain performance, faster delivery cycles and higher fulfilment accuracy -expectations that traditional wholesale setups struggle to meet.

On 24 April 2025, EVERSANA expanded its U.S. footprint with a 358,000 sq ft facility in Memphis, adding 30,000+ sq. ft of refrigerated and frozen storage and deploying AI-enabled automation to handle growing volumes of temperature-sensitive therapies. The company attributed this expansion directly to rising specialty-drug demand.

This shift is a clear driver for the market: distribution networks are being rebuilt around specialty and GLP-1 capacity. As volumes rise, wholesalers must strengthen cold-chain, automation and AI-driven fulfilment or risk being confined to lower-margin generic and OTC distribution while upgraded networks secure the premium flow of products.

Consolidation and Roll-Up Strategies Are Redrawing National Distribution Landscapes

Consolidation across wholesalers and regional distributors is accelerating as players chase national scale, portfolio breadth, and stronger leverage with manufacturers. In India, Entero Healthcare Solutions continues an active roll-up program—most notably its 2024 acquisition of Gourav Medical Agencies—to deepen coverage in core pharmaceutical distribution. Company disclosures and broker commentary indicate Entero has integrated dozens of acquisitions since 2018 to build a pan-India platform.

Globally, AscellaHealth advanced the same playbook in October 2024 by acquiring CHAPPER healthcare, a long-standing international wholesaler and distributor serving 70+ countries. These transactions highlight how scale M&A delivers operating efficiencies, wider market access, and more attractive, single-partner channels for manufacturers seeking fewer, larger, and higher-service distributors.

Where are the Market Opportunities?

Cross-Border Distribution Expansion Creates Route-to-Market Opportunities

The globalisation of pharmaceutical portfolios is creating strong opportunities for distributors that can provide manufacturers with integrated, multi-country market access. In November 2024, Celltrion acquired iQone Healthcare Switzerland, a specialty distributor already commercialising its therapies across Europe, with the aim of accelerating direct biosimilar launches and strengthening its regional presence.

Similarly, in May 2025, Ceres Pharma’s acquisition of Belgium’s Vésale Pharma was intended to reinforce its domestic position while using Vésale’s established distributor network to support broader European exports.

These transactions show how local specialist distributors are being absorbed into larger regional platforms. For wholesalers and distributors across branded, generic, OTC, vaccine and device categories, such cross-border bolt-on acquisitions provide access to higher-margin service offerings—such as regulatory support, market access and pharmacovigilance—while enabling manufacturers to streamline their European and APAC route-to-market strategies.

Specialty, Clinic-Centric and Disease-Focused Networks Offer Attractive White Space

Specialty distribution channels in oncology, urology and rare diseases are emerging as major growth opportunities for wholesalers and distributors, with 2025 marking a decisive shift toward clinic-aligned, disease-focused consolidation. In August 2025, Cardinal Health expanded its multi-specialty strategy by entering an agreement to acquire Solaris Health, one of the largest urology practice networks in the U.S. This strengthens Cardinal’s integration with physician-led specialty care and enhances its position in the distribution of high-cost drugs that depend on close alignment with clinical networks.

On the specialty wholesale front, AscellaHealth’s acquisition of CHAPPER Healthcare continues to increase its global capabilities in rare diseases and cell-and-gene therapy distribution—areas demanding high-integrity logistics, specialised handling and clinician-coordinated delivery models.

Manufacturer-side transactions further reinforce the sector’s pivot toward specialty-aligned ecosystems. In November 2025, Johnson & Johnson announced its acquisition of Halda Therapeutics, adding RIPTAC™ precision oncology programs to its pipeline. These complex, targeted modalities require controlled-access distribution, oncology network engagement and elevated supply oversight—accelerating demand for specialised wholesale partners.

Also in November 2025, Cipla’s acquisition of Inzpera Healthsciences expanded its presence in paediatric, gastrointestinal and respiratory therapies—segments where distributors must support clinic-driven fulfilment models, physician touchpoints and therapy-specific logistical requirements.

Similarly, in June 2025, McKesson completed its acquisition of Core Ventures, a multisite oncology and infusion-practice network. This integration embeds McKesson even deeper into clinic-based specialty care, aligning oncology drug distribution with real-world treatment environments and enabling higher-value services across infusion and specialty pharmacy pathways.

Collectively, these 2025 developments demonstrate that disease-focused, clinic-aligned networks offer significantly stronger margin potential than traditional volume-driven wholesale models. For distributors aiming to strengthen manufacturer partnerships and accelerate entry into high-value therapeutic segments, specialty and rare-disease networks represent one of the most compelling white-space opportunities.

Competitive Landscape

The major players operating in the Pharma Wholesale and Distribution market are AmerisourceBergen Corporation, Cardinal Health, Inc., CuraScript, Inc., Dakota Drug, Inc., Fortissa, Geo-Young Co., Ltd., Kingworld Medicines Group Limited, McKesson Corporation, Medipal Holdings Corporation, Mutual Drug, Petrone Group, Prodigy Health LLC, Sinopharm Group Co. Ltd., Smith Drug Co., Inc., and Walgreens Boots Alliance, Inc. These major players operating in this market have adopted various strategies comprising M&A, investment in R&D, collaborations, partnerships, regional business expansion, and new product launch.

Recent Developments

On 5^th November 2025, Cencora (formerly AmerisourceBergen) announced a US$1 billion investment to strengthen its U.S. pharmaceutical distribution network — including new national distribution centres and expanded capacity to support evolving demand for specialty and temperature-sensitive medicines.

On 24^th April 2025, EVERSANA announced the launch of a new 358,000 sq ft distribution facility in Memphis, featuring 30,000+ sq ft of refrigerated/frozen storage, a fully upgraded warehouse-management system, and AI-powered automation. This reflects the accelerating demand for specialty drug and cold-chain distribution capacity.

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to contactus@visiongain.com or call +44 207 336 6100.

About Visiongain

Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.